DHFR-IN-9 is a dihydrofolate reductase (DHFR) inhibitor that interferes with the biosynthesis of purines and thymidylate, thereby affecting cell proliferation and growth; it exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) ATCC43300 (IC50 = 0.25 μg/mL) and demonstrates efficacy in mouse models of systemic and thigh infections caused by MRSA (doses: 2.5 mg/kg, 5 mg/kg; intraperitoneal); it also shows superior anticancer activity compared to paclitaxel (Y-B0015) in a mouse model of breast cancer (dose: 2.5 mg/kg; intraperitoneal; once every 3 days).